Aligos Therapeutics

Meet the Aligos TeamAligos has brought together a group of remarkable individuals with years of experience and expertise. Aligos has brought together a group of remarkable individuals with years of experience and expertise. We are engaged in the discovery and development of purpose-built, potentially best-in-class small molecule and oligonucleotide drug candidates that target clinically validated mechanisms of action in NASH and viral diseases. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from November 2014 to February 2018. Blatt co-founded Alios BioPharma, Inc., a biotechnology company, and served as its Chief Executive Officer, President and Director from January 2009 until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. Chanda is a Diplomate of American Board of Toxicology (DABT). Hirth co-founded Plexxikon, Inc., a pharmaceutical company, and served as its Chief Executive Officer until April 2013. Martell served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company.